Lung Cancer

	09/25/2009	Maintenance Therapy or Exposure to Active Treatment? A Question for the NSCLC Setting
	09/08/2009	The Evolving Treatment Paradigm for Advanced NSCLC: Clinical Highlights From the 2009 Oncology Meeting in Orlando
	09/08/2009	Do New Data Justify a Role for Maintenance Therapy in Advanced NSCLC?
	09/08/2009	Are There Clinically Relevant Correlations Between Biomarker Status and Benefit From Targeted Therapies in Advanced NSCLC?
	09/08/2009	Which Novel Agents and Combinations Are Showing Promise in the Continuing Progress Towards Tailored Therapy in Lung Cancer?
	08/11/2009	Can Emerging Targeted Strategies Improve Outcomes in Advanced NSCLC?
	08/11/2009	State-of-the-Art Targeted Therapeutic Strategies for Advanced NSCLC: Front-Line and Maintenance Settings
	08/11/2009	Scanning the Horizon: An Up-to-Date Look at Potential Therapies for Advanced Recurrent/Refractory NSCLC
	08/11/2009	Ushering in an Era of Personalized Medicine in Advanced NSCLC: Predictive and Prognostic Markers as Guides for Treatment Selection
	07/09/2009	Oral Biologic Therapy versus Chemotherapy for Pretreated Non-small-cell Lung Cancer
	05/14/2009	Applying Key Biomarkers in Oncology: From Biospecimen Preparation and Storage to Clinical Implications
	05/04/2009	Applying Cell Histology, Disease-Related and Patient-Specific Characteristics to Therapy Selection in Metastatic NSCLC
	12/30/2008	Expanding the Treatment Paradigm in NSCLC: A Clinical Update of Novel Therapies From the 2008 Chicago Thoracic Oncology Meeting
	09/03/2008	Silica-Related Lung Disease: It's Still Here
	08/29/2008	Latest Data From Chicago Provide New Insight Into the Evolving Role of Cytotoxic and Targeted Therapies in Early-Stage NSCLC
	08/26/2008	Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
	08/26/2008	Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
	08/26/2008	What Is the Best Approach to Treating Alpha1-Antitrypsin (AAT) Deficiency?
	08/25/2008	Can NSCLC Treatment Be Refined? Update on New Drug Options and Factors Influencing Treatment Decisions in Advanced Disease
	08/19/2008	Latest Data From Chicago Provide New Insight Into the Evolving Role of Targeted Therapies in Advanced NSCLC
	06/11/2008	Unique Toxicity Profile of Antiangiogenic Agents Must Be Considered When Making Treatment Decisions in NSCLC
	03/26/2008	Background: Antiangiogenic Therapy in Lung and Colorectal Cancer: Patient Scenarios for Everyday Practice
	03/26/2008	Case Study 1: Optimal Management of a Patient With Stage IV NSCLC
	03/26/2008	Case Study 2: Optimal Management of a Patient With Locally Advanced CRC and Unresectable Liver Metastases
	08/01/2003	Mesothelioma Update